PharmacyCodes



Dobutaminum [Inn-Latin] en es it fr

Dobutaminum [Inn-Latin] Brand names, Dobutaminum [Inn-Latin] Analogs

Dobutaminum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Dobutaminum [Inn-Latin] Chemical_Formula

C18H23NO3

Dobutaminum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic3/dobutamine.htm

Dobutaminum [Inn-Latin] fda sheet

Dobutaminum [Inn-Latin] msds (material safety sheet)

Dobutaminum [Inn-Latin] Synthesis Reference

No information avaliable

Dobutaminum [Inn-Latin] Molecular Weight

301.38 g/mol

Dobutaminum [Inn-Latin] Melting Point

No information avaliable

Dobutaminum [Inn-Latin] H2O Solubility

No information avaliable

Dobutaminum [Inn-Latin] State

Solid

Dobutaminum [Inn-Latin] LogP

3.489

Dobutaminum [Inn-Latin] Dosage Forms

Liquid

Dobutaminum [Inn-Latin] Indication

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

Dobutaminum [Inn-Latin] Pharmacology

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Dobutaminum [Inn-Latin] Absorption

No information avaliable

Dobutaminum [Inn-Latin] side effects and Toxicity

No information avaliable

Dobutaminum [Inn-Latin] Patient Information

No information avaliable

Dobutaminum [Inn-Latin] Organisms Affected

Humans and other mammals